Mortality Rate of Ventilator-Associated Pneumonia among Critically Ill COVID-19 Patients at Maharat Nakhon Ratchasima Hospital
Keywords:
Ventilator-Associated Pneumonia (VAP), Critically Ill COVID-19 Patients, Endotracheal Intubation, Mortality RateAbstract
The coronavirus disease 2019 (COVID-19) pandemic has led to an increase in the number of patients developing acute respiratory distress syndrome (ARDS). Consequently, many patients have required admission to intensive care units and prolonged mechanical ventilation. Prolonged mechanical ventilation increases the risk of developing ventilator-associated pneumonia (VAP), which subsequently contributes to an elevated mortality rate. This study aimed to determine the mortality rate among critically ill patients with COVID-19 who developed VAP. A retrospective study was conducted using the medical records of patients with respiratory failure who required endotracheal intubation and were diagnosed with VAP while admitted to the intensive care unit and isolation ward at Maharat Nakhon Ratchasima Hospital between April 2021 and March 2022. Data were analyzed using descriptive statistics. The results showed that 26.25% of critically ill patients with COVID-19 developed VAP, and the mortality rate among these patients was as high as 71.12%. The most common pathogen identified among patients who died was extensively drug-resistant (XDR) Acinetobacter, accounting for 46.27% of cases. These findings indicate that critically ill patients with COVID-19 who develop VAP have a high risk of mortality. Therefore, knowledge of the mortality rate associated with VAP could support the development of more effective strategies for preventing and controlling VAP in the future.
References
Tsai PH, Lai WY, Lin YY, Luo YH, Lin YT, Chen HK, et al. Clinical manifestation and disease progression in COVID-19 infection. J Chin Med Assoc 2021;84(1):3–8.
Centers for Disease Control and Prevention (CDC). Monitoring incidence of COVID-19 cases. MMWR 2021;70(37):1284–90.
Department of Disease Control (TH). Coronavirus disease (COVID-19). Nonthaburi: MOPH; 2021.
Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of COVID-19 in New York City. N Engl J Med 2020;382(24):2372–4.
Vincent JL, Sakr Y, Singer M, Loeches IM, Machado FR, Marshall JC, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA 2020;323(15):1478–87.
Póvoa HCC, Chianca GC, Iorio NLPP. COVID-19: An Alert to Ventilator-Associated Bacterial Pneumonia. Infect Dis Ther 2020;9(3):417–20.
Maes M, Higginson E, Pereira-Dias J, Curran MD, Parmar S, Khokhar F, et al. Ventilator-associated pneumonia in critically ill patients with COVID-19. Crit Care 2021;25(1):25.
Rouzé A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med 2021;47(2):188–98.
Montrucchio G, alzani E, Sales G, Vaninetti A, Grillo F, Trompeo AC, et al. Multidrug-resistant pathogens and ventilator-associated pneumonia in critically ill COVID-19 and non-COVID-19 patients: a prospective observational monocentric comparative study. Respir Res 2024;25(1):168.
Rouyer M, Strazzulla A, Youbong T, Tarteret P, Tarteret A, Pontfarcy Ad, et al. Ventilator–Associated Pneumonia in COVID-19 Patients: A Retrospective Cohort Study. Antibiotics (Basel) 2021;10(8):988.
Vacheron CH, Lepape A, Savey A, Savey A, Timsit JF, Comparot S, et al. Attributable Mortality of Ventilator-associated Pneumonia Among Patients with COVID-19. Am J Respir Crit Care Med 2022,206(2):161–9.
Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020;395(10229):1014–5.
Grasselli G, Grasselli A, Grasselli A, Grasselli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.JAMA 2020;323(16):1574–81.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 The Office of Disease Prevention and Control 9 Nakhon Ratchasima
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the Journal of the Office of Disease Prevention and Control 9 Nakhon Ratchasima are the copyrighted property of the Office of Disease Prevention and Control 9 Nakhon Ratchasima.
